Great Lakes Advisors LLC Decreases Stock Holdings in Pediatrix Medical Group, Inc. $MD

Great Lakes Advisors LLC reduced its position in Pediatrix Medical Group, Inc. (NYSE:MD) by 49.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 168,123 shares of the company’s stock after selling 164,723 shares during the period. Great Lakes Advisors LLC owned 0.19% of Pediatrix Medical Group worth $2,816,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MD. Royal Bank of Canada grew its holdings in Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock worth $320,000 after purchasing an additional 4,247 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Pediatrix Medical Group by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after purchasing an additional 2,251 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Pediatrix Medical Group by 4.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock worth $3,891,000 after buying an additional 12,171 shares during the last quarter. State of Alaska Department of Revenue increased its position in Pediatrix Medical Group by 7.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 50,096 shares of the company’s stock valued at $717,000 after buying an additional 3,262 shares in the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Pediatrix Medical Group by 8.7% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 11,913 shares of the company’s stock valued at $171,000 after buying an additional 950 shares during the last quarter. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Insider Transactions at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Michael A. Rucker sold 10,478 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $23.00, for a total value of $240,994.00. Following the sale, the director owned 59,101 shares in the company, valued at approximately $1,359,323. This represents a 15.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Mark S. Ordan sold 23,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares in the company, valued at $6,785,860.05. The trade was a 7.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 43,478 shares of company stock worth $972,924 over the last quarter. 0.90% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. UBS Group upped their price objective on shares of Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Wall Street Zen raised shares of Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Finally, Truist Financial upped their target price on Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, November 10th. One analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Pediatrix Medical Group currently has an average rating of “Hold” and an average price target of $21.00.

Pediatrix Medical Group Stock Up 1.8%

MD stock opened at $21.38 on Friday. The company has a market capitalization of $1.84 billion, a P/E ratio of 11.25 and a beta of 0.73. Pediatrix Medical Group, Inc. has a 12 month low of $11.84 and a 12 month high of $24.99. The firm’s fifty day simple moving average is $22.20 and its 200-day simple moving average is $18.73. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Monday, November 3rd. The company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.21. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The company had revenue of $492.88 million during the quarter, compared to the consensus estimate of $476.45 million. During the same period in the previous year, the firm posted $0.44 earnings per share. The firm’s quarterly revenue was down 3.6% on a year-over-year basis. As a group, equities research analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.